Latest News & Updates
Full Agenda Now Available
See what’s in store across two days of practical discussions on IP due diligence, deal risk, licensing, patent strategy, and life sciences transactions.
View AgendaBest Rates End November 13
Save $300 when you register by November 13 and lock in the best available rate.
Register NowThe Essential Summit for IP Due Diligence Professionals
The life sciences dealmaking world is changing, and your IP due diligence has to keep up. This February, join leading in-house counsel, private practice attorneys, and industry experts for two days of practical guidance on evaluating intellectual property assets, mitigating risk, and maximizing deal value in today’s complex global business environment.
Designed for professionals involved in mergers and acquisitions, licensing, collaborations, financings, and strategic partnerships, this annual summit delivers actionable insights into the legal, commercial, and operational issues shaping life sciences IP due diligence now.
Join us to explore topics including:
- Best practices for conducting comprehensive IP due diligence
- Identifying and mitigating legal and commercial risks
- Evaluating patent portfolios, trade secrets, and licensing and funding arrangements
- Emerging litigation and policy developments impacting life sciences transactions
- Practical strategies to strengthen diligence processes and support successful deals
Meet the Conference Co-Chairs
Learn from the leaders who helped shape this year’s agenda.
Robert Furlani
Assistant General Counsel & Chief Patent Counsel
Ligand Pharmaceuticals
Thomas L. Irving
Senior Partner
The Marbury Law Group, PLLC
Erica Norey
Senior Counsel IP for Global Business Development & M&A
Sanofi
Featured In-House Speakers
Hear directly from senior legal and IP leaders as they share practical insights on navigating IP due diligence, transactions, and strategic partnerships in the life sciences sector.
Jennifer Friel Goldstein
Head of Relationship Management; Technology & Healthcare Banking
Silicon Valley Bank, a division of First Citizens Bank
Donna Meuth
Associate General Counsel Intellectual Property
Eisai Inc.
Christine Norris
Senior Corporate Counsel, Intellectual Property
Charles River
Victoria Pedanou, PhD JD
Counsel, Global Biologics Intellectual Property, Legal, Ethics & Business Integrity
Sanofi
Michael Penn
Vice President, IP
BlueRock Therapeutics
Christine Rea Prihoda
Counsel, Strategic Transactions and M&A
Gilead Sciences Inc
View All Speakers
Past Attending Organizations
- AMRI
- Allergan plc
- AtriCure Inc
- Azurity Pharmaceuticals Inc
- BONWRx
- Beck & Thomas
- Biogen
- Blaze Bioscience Inc
- BlueRock Therapeutics
- Boehringer Ingelheim International GmbH
- Boston University (CARB-X)
- Brammer Bio
- Brinks Gilson & Lione
- Centre for Drug Research and Development
Testimonials
“Unique high level sessions, good mix of in-house and outside counsel.”
“Hearing from professionals involved in due diligence on a daily basis was very informative.”
“Great panels, lots of diversity of practice, and lots of seasoned practitioners.”
“The design of the event brought us all together along with room intimacy.”
Sponsors & Partners
Supporting Sponsor
Associate Sponsors
Media Partners
Sponsor Opportunities
With conferences in the United States, Europe, Asia Pacific, and Latin America, the C5 Group of Companies: American Conference Institute, the Canadian Institute, and C5 Group, provides a diverse portfolio of conferences, events and roundtables devoted to providing business intelligence to senior decision makers responding to challenges around the world.
For more information please contact:
Aaron Goldstein
Senior Business Development Manager
Email: [email protected]
